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Abstract
Background: In spite of recent advances in post-operative pain relief, pain following orthopedic surgery remains an 
ongoing challenge for clinicians. We examined whether a well known and frequently prescribed homeopathic 
preparation could mitigate post-operative pain.
Method: We performed a randomized, double blind, placebo-controlled trial to evaluate the efficacy of the 
homeopathic preparation Traumeel S® in minimizing post-operative pain and analgesic consumption following 
surgical correction of hallux valgus. Eighty consecutive patients were randomized to receive either Traumeel tablets or 
an indistinguishable placebo, and took primary and rescue oral analgesics as needed. Maximum numerical pain scores 
at rest and consumption of oral analgesics were recorded on day of surgery and for 13 days following surgery.
Results: Traumeel was not found superior to placebo in minimizing pain or analgesic consumption over the 14 days of 
the trial, however a transient reduction in the daily maximum post-operative pain score favoring the Traumeel arm was 
observed on the day of surgery, a finding supported by a treatment-time interaction test (p = 0.04).
Conclusions: Traumeel was not superior to placebo in minimizing pain or analgesic consumption over the 14 days of 
the trial. A transient reduction in the daily maximum post-operative pain score on the day of surgery is of questionable 
clinical importance.
Trial Registration: This study was registered at ClinicalTrials.gov. # NCT00279513
Background
The management of postoperative pain following ambu-
latory orthopedic surgery is an issue of ongoing concern
for patients and for physicians performing these proce-
dures. Numerous studies have found pain control to be
i n a d e q u a t e  [ 1 - 6 ] .  P a i n  i s  t h e  m o s t  f r e q u e n t  c a u s e  o f
delayed discharge and unanticipated readmission follow-
ing ambulatory surgery [7,8], as well as for contacting the
family physician after discharge [9]. Nearly a third of
patients have moderate to severe pain 24 hours after
ambulatory surgery [10], while eleven percent experience
severe pain [11]. Both moderate and severe pain can last
for up to a week after surgery [9]. Treatment for post-
operative pain typically includes anti-inflammatory med-
ications and opiates, both of which are associated with
adverse effects, limiting patient compliance and effective-
ness.
Traumeel S® is an over-the-counter homeopathic prepa-
ration composed of extracts from a combination of plants
and minerals that have been highly-diluted, though not
beyond Avogadro's number (see Table 1). It has been
widely sold in German, Switzerland and Austria for over
50 years, and is one of the most popular alternative medi-
cations in these countries, selling approximately four mil-
lion doses a year [manufacturer information]. Earlier
studies have suggested that Traumeel may be effective in
trauma [12-15], acute tendinopathy [16] and in the spinal
syndrome [17], though these studies were either non-ran-
domized or used poorly chosen controls. A small RCT
found Traumeel to be effective in post-chemotherapy
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stomatitis [18]. While the mechanism of action of this
preparation remains unknown, recent research has
shown that Traumeel reduces secretion of pro-inflamma-
tory cytokines from various human immune cells in vitro,
both at rest and when activated by PHA-, PMA-, or TNF-
α. Interleukin-1β secretion was reduced by 70%, TNF-α
by 65% and 54% (resting and activated), and IL-8 by 50%
(P < 0.01 for all comparisons) [19].
U n pub lis hed da ta  fr om  a  m a n u fact u r e r sa f et y s urvey
indicated adverse events in 0.0035% of 3.5 million cases
[personal communication]. These appeared almost
entirely in cases where Traumeel was injected, with the
most common of these events being local irritation at the
site of injection that resolved spontaneously after discon-
tinuation of treatment. No drug interactions are known
with this preparation [manufacturer information].
In 2007 we published the results of an open pilot study
to evaluate the efficacy of Traumeel in mitigating post-
operative pain following ambulatory hallus valgus surgery
[20]. In this study, treatment allocation was by week of
surgery rather than by strict randomization. This study
found significantly lower post-operative pain scores in
patients treated with supplementary Traumeel as com-
pared with standard care alone. To the best of our knowl-
edge, no randomized controlled trial has yet assessed the
effectiveness of Traumeel for the relief of acute pain in
patients following ambulatory surgery. We therefore per-
formed a randomized, double-blind, placebo-controlled
clinical trial to evaluate the efficacy of Traumeel in con-
trolling post-operative pain after ambulatory hallus val-
gus correction.
Methods
Study design
The study was designed, conducted, and reported
according to the Consolidated Standards of Reporting
Trials (CONSORT) guidelines [21], and approved by the
ethics committees of the Shaare Zedek Medical Center
(SZMC) and the Meir Medical Centers (MMC). All
patients scheduled for ambulatory hallus valgus surgery
Table 1: Composition of the homeopathic-complex Traumeel S®.
Component Homeopathic dilution Quantity per tablet
Arnica Montana D2 150 μg
Calendula officinalis D2 150 μg
Atropa belladonna D4 7.5 μg
Aconitum napellus D3 30 μg
Bellis perennis D2 60 μg
Hypericum perforatum D2 30 μg
Echinacea angustifolia D2 60 μg
Echinacea purpurea D2 60 μg
Hepar sulfuris D8 300 pg
Symphytum officinale D8 240 pg
Matricaria Chamomilla D3 24 μg
Achillea millefolium D3 15 μg
Mercurius solubilis Hahnemanni D8 300 pg
μg = microgram (1/1,000,000 g), pg = picogram (1/1,000,000,000 g)Singer et al. BMC Clinical Pharmacology 2010, 10:9
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at the Shaare Zedek Medical Center department of ortho-
pedics between 12 September 2006 and 19 November
2007, and at Meir Medical Center between 1 August 2007
and 19 November 2007 were screened for inclusion in the
trial. The exclusion criteria were as follows: age under 18
years, bilateral surgery, previous hallus valgus surgery on
the ipsilateral foot, diseases possibly effecting wound
healing or pain sensation (uncontrolled diabetes mellitus,
Berger's disease, deep vein thrombosis, peripheral vascu-
lar disease), sensitivity to any of the study medications
and technical or cognitive inability to comply with the
study protocol. Eighty consecutive patients who fulfilled
all inclusion and no exclusion criteria and who signed
informed consent were enrolled in the trial.
Study design was randomized and double-blind. Ran-
domization blocks of four subjects were created, and then
selected using random number sequence. The HEEL
Company (Baden-Baden, Germany) prepared and sup-
plied the study medication or an indistinguishable pla-
cebo in 100 consecutively numbered, sealed boxes,
according to the randomization list. Sealed copies of the
randomization list were held by the manufacturer and a
hospital physician not otherwise involved in the trial.
These were to be opened only in the event of a medical
emergency necessitating knowledge of the treatment allo-
cation of a given patient. Otherwise, patient and all study
personnel remained unaware of treatment allocation
until the trail was completed and the database sealed, at
which point the allocation envelopes were to be opened
and the randomization code unveiled. Each eligible
patient was assigned the lowest numbered box available.
Surgery was performed as orthopedically indicated, with
all patients anesthetized using an ankle block of 20 cc
Lidocaine 1% and Marcaine 0.5%. Upon completion of
surgery, patients were instructed to take two tablets of the
study medication five times daily for the first three days,
and three times daily afterwards. The composition of
Traumeel tablets is displayed in Table 1. Patients also
received tablets of paracetamol 325 mg with codeine 15
mg (Cod-Acamol Forte, Teva Pharmaceutical Industries,
Israel) as primary analgesic, to be taken in a two-tablet
dose up to six times daily, as needed. Patients additionally
received a prescription for Tramadol tablets 100 mg (Tra-
madex, Dexcel Pharma, Israel) as rescue analgesic to be
taken as needed, up to a maximum of four tablets a day.
The choice of a primary analgesic including a mild opiate
was based upon the necessity for standardized primary
analgesia while offering patients adequate pain relief over
the course of the trial. Previous experience had indicated
that non-opiate analgesics were insufficient for this pur-
pose. Patients were instructed to record maximal daily
pain scores at rest using a self-administered, horizontal
11-point numerical rating score (NRS-11), graded from 0
(no pain) to 10 (worst imaginable pain). Patients were fur-
ther requested to record in the patient diary the number
of primary and rescue analgesic tablets taken, and the
maximum level of pain at rest they had experienced dur-
ing that day.
Patients were contacted by telephone every evening by
a study nurse, who recorded the reported NSR and anal-
gesic consumption values in the case report form. The
nurse also encouraged study compliance. Patients were
instructed to withhold study medication if the NRS score
was three or less and no other analgesics had been con-
sumed for two consecutive days. Patients were examined
by a surgeon on days 6 and 13 days after surgery, and any
adverse events, related or unrelated to treatment, were
registered. On post-operative day 13, all study materials
were collected from the patient.
Efficacy measures
The primary outcome measure was maximum daily pain
at rest, as measured by a horizontal, 11-point numerical
rating scale (NRS-11) filled out on the day of surgery (day
0) and for 13 post-operative days. Secondary outcomes
were total consumption of primary analgesics and num-
ber of days requiring rescue analgesics. Adverse events
were monitored throughout the study.
Statistical analysis
Statistical analysis was performed following the inten-
tion-to-treat principle. To compare the post-operative
pain between the study groups, the area-under-the-curve
(AUC) of the NRS pain scores recorded daily over the 2
weeks post-operative was used. We chose the AUC for
both clinical and statistical reasons. Clinically, it summa-
rizes the strength of pain and the number of days the
patient experienced pain. Statistically, it is a summary
measure which allows one to deal with repeated measure-
ments with no need to adjust for the type 1 error rate. For
each patient, an AUC was obtained by graphing the NRS
pain scores recorded every day during follow-up, linking
time-adjacent points by a straight line and calculating the
area under the resulting polygon. When all 14 pain scores
are available, this is equivalent to the sum of the 14
scores. Linear interpolation was performed to estimate
the NRS score on those days that were missing. The mean
AUCs were compared between study groups using the
Mann-Whitney test. The repeated measures mixed
model was used to test for an interaction between time
and treatment allocation. Mann-Whitney tests were used
to compare the total amount of primary analgesics con-
sumed and the total number of days taking rescue analge-
sics. Post-hoc subgroup analysis was performed to assess
the influence of type of surgery on post-operative pain
scores. Surgical procedures were characterized as 'Chev-Singer et al. BMC Clinical Pharmacology 2010, 10:9
http://www.biomedcentral.com/1472-6904/10/9
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Table 2: Baseline demographic and clinical variables of the Traumeel S® and placebo treatment groups.
Traumeel S®
(n = 39)
Placebo
(n = 40)
Clinical Center:
SZMC* 33 34
MMC** 6 6
Age (y)
Mean (SD) 48.1 (16.7) 45.2 (18.7)
< 50 17 19
≥ 50 22 21
Sex (%)
M 8 (20.5) 8 (20.0)
F 31 (79.5) 32 (80.0)
Ethnicity/Origin (%)
Europe/America 12 (30.8) 9 (22.5)
Asia/Africa 21 (53.9) 25 (62.5)
Israeli Arab 2 (5.1) 0
Mixed 2 (5.1) 2 (5.0)
Other 2 (5.1) 4 (10.0)
BMI
Mean (SD) 24.7 (4.1)† 24.3 (4.0)†
< 24 20 23
≥ 24 18 16
Pain before surgery
Mean (SD) 5.4 (2.8) 5.7 (2.6)†
< 6 19 18
≥ 6 20 21
Laterality (%)
Right 21 (53.9) 14 (35.9)†
Left 16 (41.0) 24 (61.5)
Bilateral# 2 (5.1) 1 (2.6)
Type of surgery (%)
Chevron - only 9† (23.0) 10†† (26.3)
Additional 17 (43.5) 18 (47.3)
osteotomy
Triple or 13 (33.3) 10 (26.3)
proximal
osteotomy
* SZMC -- Shaare Zedek Medical Center
**MMC -- Meir Medical Center
#3 patients had a bilateral hallux valgus but underwent surgery on only one foot.
† - includes 1 patient with missing data.
††-includes 2 patients with missing data.Singer et al. BMC Clinical Pharmacology 2010, 10:9
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ron only', 'Additional osteotomy', or 'Triple or proximal
osteotomy', and Mann-Whitney tests were performed in
each subgroup to compare the area-under-the-curve of
the NRS pain scores between treatment arms. Frequency
of the main adverse events was compared using Fisher's
exact test. Sample size was calculated using a conserva-
tive interpretation of the data obtained in our previous
pilot study [20], a type I error of 0.05, a power of 90% and
a 15% loss to follow-up.
Results
Patient flow throughout the study is presented in Figure
1. Of the 80 patients who participated in the trial, 79 were
evaluable for intention-to-treat analysis. The remaining
Figure 1 Flow chart of patients through study. 172 patients were screened for participation in the trial. Of 80 patients randomized, one discontin-
ued treatment and was excluded from analysis.
 
 
 
 
 
 
 
Randomized 
n = 80 
Patients screened 
n = 172 
Excluded: (n = 92) 
Not meeting inclusion 
criteria: 34 
Refused participation: 34 
Surgery deferred: 24 
Analyzed (39) 
Excluded from 
analysis: (0) 
Analyzed (40) 
Excluded from 
analysis: (1) 
Lost to follow-up: (0) 
Discontinued 
intervention: (1) 
Lost to follow-up: (0) 
Discontinued 
intervention: (0) 
Traumeel S (n = 39) 
Received allocated 
intervention: (39) 
Placebo (n = 41) 
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patient withdrew consent on the third day of the trial
because of nausea, vomiting and abdominal pain. He did
not provide sufficient data points to be included in the
final analysis. Patient groups were balanced with respect
to all baseline parameters except for laterality of surgery
(Table 2).
Overall, the mean area-under-the-curve pain scores
during the 14 days of the trial were not significantly dif-
ferent between the groups (55.4 ± 25.5 in Traumeel group
vs. 57.4 ± 25.7 for placebo, p = 0.89). However, the mean
pain score on the day of surgery appeared lower in the
Traumeel group than placebo (4.0 vs. 5.6, Figure 2). This
difference is supported by the test for interaction
between time and treatment group (p = 0.04).
When stra tified for type of sur gery , in t he Chevr on-
only strata the mean pain score appeared lower in the
Traumeel group than in the placebo group, however this
difference was not found statistically significant
(Traumeel - 46.1, Placebo - 61.8, p = 0.35). In the 'Addi-
tional osteotomy' and ' Triple or proximal osteotomy'
groups, differences in mean pain between the verum and
placebo groups were negligible (Table 3).
There was little difference between the two arms in the
total number of tablets of primary analgesics consumed
(15.6 ± 12.2 for Traumeel vs. 16.0 ± 11.9 for placebo, p =
0.74) and in the number of days on which rescue analge-
sics were required (mean ± SD: 1.0 ± 3.1 for Traumeel
and 1.5 ± 2.0 for Placebo, p = 0.99).
Four patients in the placebo group (10%) and two in the
Traumeel group (5.1%) developed wound infection. Six
patients in the Traumeel group (15%) and four patients in
the placebo group (10%) developed nausea and/or vomit-
ing, though these differences were not statistically signifi-
cant (p = 0.51 and p = 0.68 respectively). In the Traumeel
group, one 82-year-old patient with type II diabetes
developed cellulitis following wound infection. He was
hospitalized for intravenous antibiotic treatment, but did
not require further surgery. This was deemed a serious
adverse event unrelated to the study medication.
Discussion
Traumeel was not superior to placebo in minimizing pain
or analgesic consumption over the 14 days of the trial,
however a transient reduction in the daily maximum
post-operative pain score was observed on the day of sur-
gery. Our statistical design did not allow for a significance
test specific to that day, however a test for interaction was
significant. Stratification by type of surgery did not alter
these results. Because post-operative pain is maximal in
the period immediately following surgery, this finding
may be of clinical importance. Wound infection was
more prevalent in the placebo group, but the difference
was not statistically significant. Other adverse effects
were too rare to analyze statistically.
Our findings do not support those of a pilot study pub-
lished in 2007 that suggested a 30% improvement in pain
over 14 post-operative days, and a non-significant trend
towards lower analgesic consumption. In that non-
blinded study, 30 subjects were allocated by week of sur-
gery to intraoperative injection of Traumeel, injection
plus oral Traumeel, or no treatment. Both treatment arms
Figure 2 Mean pain score over the 14 days of the trial. Mean NRS 
pain scores over 14 days for 79 patients receiving Traumeel S® or Place-
bo. The error bars indicate the mean plus or minus 1 standard error.
Table 3: Pain score stratified for type of surgery.
Chevron-only Additional osteotomy Triple or proximal osteotomy
AUC Traumeel (n =
9)
Placebo (n =
10)
Traumeel (n =
17)
Placebo (n =
18)
Traumeel (n =
13)
Placebo (n =
10)
M e a n 4 6 . 16 1 . 86 3 . 15 9 . 55 1 . 64 9 . 2
S D 2 3 . 43 4 . 12 5 . 65 5 . 54 9 . 04 9 . 0
p-value 0.35 0.69 0.88
AUC -- Area Under the CurveSinger et al. BMC Clinical Pharmacology 2010, 10:9
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were found superior to no treatment [20]. Differences in
study methodology could explain the differences in out-
come. W e believe that future research should focus on
the early post-operative period.
Homeopathy is frequently attacked for its use of solu-
tions diluted beyond Avogadro's number, and hence
physical-chemical implausibility. That criticism was cir-
cumvented in this trial by employing a preparation of
solutions that were dilute, but well within the material
range.
Relief of post-operative pain remains an ongoing chal-
lenge. While other treatment modalities have been exam-
ined, each has its own limitations. Valdecoxib and
rofecoxib have both been found effective for relief of pain
following hallux valgus surgery [22,23] but were removed
from the market amid concerns of excessive risk of heart
attack and stroke. Betamethasone has been found to
reduce post-operative pain and nausea [24], but concerns
remain regarding the effect of corticosteroids on post-
operative healing [25]. Parenteral routes for delivery of
opiates are available, but they entail greater cost, com-
plexity, and possible need for hospitalization [26].
This trial has several limitations. By choosing a cumula-
tive 14-day measure for our primary outcome, we may
have inadvertently diluted any effect that may have been
present in the first days after surgery - those with the
greatest pain. Homeopathic purists may find fault in the
administration of a standardized combination homeo-
pathic formula to all patients, based upon clinical diagno-
sis - as opposed to the individualized manner dictated by
standard homeopathic practice. We were aware of this
limitation at the outset; however, performing an individu-
alized RCT would be far more complex, time-consuming,
and fraught with methodological pitfalls. The mode of
administration of the remedy may have played a role as
well. In contrast to our pilot study, in the current study,
for the sake of simplicity we chose to use only oral admin-
istration of the study medication, under the assumption
that its effect would be similar to that of injection fol-
lowed by oral therapy. In retrospect, that assumption may
have been mistaken.
Conclusions
The homeopathic complex Traumeel S® was not found
superior to placebo in mitigating post-operative pain or
analgesic consumption over the 14 days of the trial. A
transient reduction in the daily maximum post-operative
pain score, observed on the day of surgery, is of question-
able importance. We recommend repetition of this trial,
but using injected Traumeel and focusing on the early
post-operative period.
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